Our ADC co-development agreements with Astellas and Genmab provide Seattle Genetics with opportunities to supplement our internal pipeline through opt-in rights to 50:50 co-development and profit-sharing for ADC product candidates. You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. Tucatinib is an orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is over-expressed in multiple cancers, including breast, colorectal, and gastric cancers.
Under the collaboration, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has commercialization rights in the rest of the world.
Seattle Genetics is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology delivering cancer-killing therapy to tumor cells.
Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. A diverse pipeline designed to address significant unmet medical needs.
This resource link is for informational purposes only. The companies are funding joint worldwide development costs on a 50:50 basis, except in Japan where …
... You are now leaving Seattle Genetics' site. Under these collaborations, we are co-developing enfortumab vedotin with Astellas and tisotumab vedotin with Genmab. This resource link is …